Cevimeline - Daiichi Sankyo
Alternative Names: AF 102B; Cevimeline hydrochloride; Evoxac; FKS 508; Saligren; SND 5088; SNI 2011; SNK 508Latest Information Update: 05 Nov 2023
At a glance
- Originator Israel Institute for Biological Research
- Developer Daiichi Sankyo Company; Nippon Kayaku; SnowBrand Pharmaceuticals
- Class Quinuclidines; Small molecules; Thiophenes
- Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M3 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Xerostomia
- Discontinued Alzheimer's disease